1   *Streptococcus pyogenes* colonization in children aged 24-59 months in The Gambia: Impact

2   of Live Attenuated Influenza Vaccine and associated serological responses

Alexander J. Keeley[1,2,3], Danielle Groves[2], Edwin P. Armitage[1,3], Elina Senghore[3], Ya Jankey

Jagne[3], Hadijatou J. Sallah[3], Sainabou Drammeh[3], Adri Angyal[2], Hailey Hornsby[2], Gabrielle

de Crombrugghe[4,5], Pierre Smeesters[4,5], Omar Rossi[6], Martina Carducci[6], Chikondi Peno[7],

Debby Bogaert[7], Beate Kampmann[1,3], Michael Marks[1,8,9], Helen A. Shaw[10], Claire E.

Turner[11] and Thushan I. de Silva[1,2,3] on behalf of MRCG Strep A Study Group^.

1.   Faculty of Infectious and Tropical Diseases, The London School of Hygiene &

Tropical Medicine, Keppel Street, London, United Kingdom

2.   Department of Infection, Immunity and Cardiovascular Disease, Medical School, The

University of Sheffield, Sheffield, United Kingdom

3.   Vaccines and Immunity Theme, MRC Unit The Gambia at LSHTM, PO Box 273,

Banjul, The Gambia

4.   Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels,

Belgium.

5.   Department of Pediatrics, Hôpital Universitaire des Enfants Reine Fabiola, Université

Libre de Bruxelles, 1050 Brussels, Belgium.

6.   GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena,

Italy

7.   Centre for Inflammation Research, Queen's Medical Research Institute, University of

Edinburgh, Edinburgh, UK

8.   Hospital for Tropical Diseases, University College London Hospital, London, UK

9.   Division of Infection & Immunity, University College London, London, UK

10.   Vaccines Division, Scientific Research & Innovation Group, MHRA, Potters Bar, UK

11.   School of Biosciences, The University of Sheffield, Sheffield, United Kingdom

^A full list of MRC Unit The Gambia StrepA Study Group members is listed in

acknowledgements.

32
33

Abstract

Background

Immunity to *Streptococcus pyogenes* in high burden settings is poorly understood. We explored

S. pyogenes nasopharyngeal colonization after intranasal live attenuated influenza vaccine

(LAIV) among Gambian children aged 24-59 months, and resulting serological response to 7

antigens.

Methods

A post-hoc analysis was performed in 320 children randomized to receive LAIV at baseline

(LAIV group) or not (control). *S. pyogenes* colonization was determined by quantitative

Polymerase Chain Reaction (qPCR) on nasopharyngeal swabs from baseline (D0), day 7 (D7)

and day 21 (D21). Anti-streptococcal IgG was quantified, including a subset with paired serum

pre/post *S. pyogenes* acquisition.

Results

The point prevalence of *S. pyogenes* colonization ranged from 7-13%. In children negative at

D0, *S. pyogenes* was detected at D7 or D21 in 18% of LAIV group and 11% of control group

participants (p=0.12). The odds ratio (OR) for colonization over time was significantly

increased in the LAIV group (D21 vs D0 OR 3.18, p=0.003) but not in the control group (OR

0.86, p=0.79). The highest IgG increases following asymptomatic colonization were seen for

M1 and SpyCEP proteins.

Conclusions

Asymptomatic *S. pyogenes* colonization appears modestly increased by LAIV, and may be

immunologically significant. LAIV could be used to study influenza-*S. pyogenes* interactions.

Word count:

Main text: 3478 (excluding 446 for figure legends)

Abstract: 200

Keywords:

Streptococcus pyogenes

Colonization

Carriage

The Gambia

Live Attenuated Influenza Vaccine

Serological responses

Antibodies

Introduction

Streptococcus pyogenes (Group A Streptococcus, Strep A) is responsible for half a million deaths worldwide each year, through severe invasive infections and immune complications including rheumatic heart disease (RHD)[1]. The greatest disease burden is experienced in low- and middle-income countries (LMIC)[1, 2]. Consequently, the World Health Assembly declared in 2018 that a vaccine against *S. pyogenes* is a major global health research priority. An ideal vaccine would substantially reduce *S. pyogenes* transmission, disease, and perhaps colonization, without provoking immune mediated complications [3]. Observational data show a decrease in the incidence of *S. pyogenes* disease with increasing age, possibly due to natural immunity acquired from repeated exposure [4]. Asymptomatic pharyngeal colonization with *S. pyogenes* is recognized, with an estimated point prevalence of 6.6-9.7% in children [4]. Characterizing protective immunity generated by infections and colonization remains a major knowledge gap in designing effective and safe vaccines, particularly from LMIC settings [5-7].

Epidemiological observations have shown an association between invasive *S. pyogenes* infections and respiratory viral infections, especially influenza [8]. *S. pyogenes* was demonstrated to be responsible for substantial mortality in influenza pandemics of 1918 and 2009 [8, 9]. It is important to understand whether respiratory viruses increase colonization with pathogenic bacteria such as *S. pyogenes* in the nasopharynx, as colonization may be a necessary preceding event to pharyngitis and invasive disease. We have recently demonstrated that intranasal live attenuated influenza vaccine (LAIV), used as a surrogate viral challenge agent, induces modest increases in nasopharyngeal *Streptococcus pneumoniae* colonization and density in the 21 days following vaccination in Gambian children [10]. In the current study, we conducted a post-hoc analysis of this randomized controlled trial of LAIV in children aged 24-59 months to explore whether LAIV also induced an increase in nasopharyngeal *S.*

pyogenes colonization, and whether colonization was associated with a serological response to

several *S. pyogenes* antigens.

Methods

<u>Study population and design</u>: We carried out a post-hoc observational study nested within a

randomized controlled trial of LAIV, studying immunogenicity, viral shedding and

microbiome interactions in children aged 24-59 months in The Gambia. Children were

randomized 2:1 to receive LAIV at study entry (day 0, D0, LAIV group) or on day 21 (D21,

control group), which was the end of active follow up. The study (NCT02972957) was

conducted across two years in Sukuta, an urban region in The Gambia, Africa during February

to April 2017, and January to March 2018 [10, 11]. Children were recruited to the parent study

following community sensitization. All participants were influenza-vaccine naïve and

clinically well, with no history of respiratory illness in the prior 14 days. Participants in LAIV

and control groups were recruited simultaneously to avoid bias via seasonal variation. Children

were immunized with the Northern Hemisphere Russian-backbone Trivalent LAIV (Nasovac-

S, Serum Institute of India, Pune, India)[11]. Data on symptoms experienced between D0 and

D7 were collected at the D7 visit, and symptoms experienced between D7 and D21 recorded

at the D21 visit. Informed consent was sought from parents of all participants, including for

subsequent research on their samples. The study was approved by the Joint Medical Research

Council/Gambia Government ethics committee (ref: 16193).

<u>Determination of *S. pyogenes* colonization status</u>: Participants had a nasopharyngeal swab

taken at D0 (immediately prior to LAIV receipt), at D7 and D21, using flocked swabs

(FLOQSwabs; Copan, USA) stored in RNAprotect (Qiagen, UK). Samples were processed

within 4 h of collection and stored at −70°C until further processing. DNA was extracted from

200μl of RNAprotect using the AGOWA Mag Mini DNA extraction kit (LGC Genomics, Berlin, Germany) in combination with phenol-bead beating as previously described[12]. Standard curves were generated via extraction of total genomic DNA from the *S. pyogenes* H293 reference strain, ranging from 1 to 10,000,000 genome copies per μL. Quantitative PCR was performed using QuantStudio™ 5 Real-Time PCR System, using primers and probes to detect the *S. pyogenes* specific gene *speB* (Forward: CTAAACCCTTCAGCTCTTGGTACTG, Reverse: TTGATGCCTACAACAGCACTTTG, Probe: Cy5-CGGCGCAGGCGGCTTCAAC-BHQ2) [13]. A cycle threshold of 40 was defined as positive, but all curves above CT threshold of 35 were checked manually to ensure appearance was consistent with true amplification of the target. Samples were run in triplicate. Where only one of the triplicates showed the presence of *S. pyogenes*, samples were repeated and only defined as positive if at least two triplicates were positive on repeat testing. A participant with positive qPCR result at a given timepoint was considered colonized. All participants were included in the colonization study group. Participants who were negative at baseline were included in the acquisition study group (figure 1).

Antibody measurement: Blood was collected in serum separation tubes from participants in the LAIV group, for study endpoints on influenza vaccine immunogenicity [11]. For the serology study participants were categorised as colonized if *S. pyogenes* was detected by qPCR at any time point. Participants in the acquisition study group (negative at day 0) were categorised as newly-colonized if *S. pyogenes* was detected at either D7 or D21. All available serum collected on D21 from colonized participants was tested, along with a random selection from non-colonized participants (a 1:1.5 ratio of colonized to non-colonized participants). Of newly-colonized participants, a subgroup of 18 had paired serum (pre/post colonization) available for testing.

Enzyme-linked immunosorbent assay (ELISA) optimization was performed to determine

optimal *S. pyogenes* protein coating concentrations, blocking buffer solution, serum dilution

and secondary antibody concentration. 96-well flat-bottomed high binding ELISA plates were

coated overnight with several recombinant proteins in pH 9.6 carbonate buffer: *S. pyogenes*

cell envelope protease (SpyCEP) at 0.16μg/ml, *S. pyogenes* Adhesion and Division protein

(SpyAD) at 1μg/ml, M1 protein at 0.5μg/ml, Mac/IdeS protein (henceforth referred to as Mac)

at 1 μg/ml, and Collagen binding protein (Cpa) at 0.16 μg/ml. Proteins were provided by

National Institute for Biological Standards and Control, MHRA, UK (Supplementary

data)[14]. Blocking and serum dilution was performed using 1% casein blocking buffer

(ThermoFisher Scientific, USA). Serum was diluted to 1:100 for Cpa and Mac, and 1:800 for

M1, SpyCEP and SpyAD, and applied to protein coated wells. Bound IgG was detected with

goat anti-human IgG-HRP conjugate (Invitrogen, USA), diluted to 1:500, then incubated with

SureBlue TMB 1-Component Peroxidase Substrate (KPL). The reaction was stopped with 1%

hydrochloric acid and optical density (OD) was read at 450nm, subtracting background OD.

Six washes were performed between each ELISA step with 0.05% Tween-20 in phosphate

buffered saline (PBS). In order to quantify anti-protein IgG activity in participant sera, 12 serial

three-fold dilutions of pooled human immunoglobulin (Gammanorm, Octapharm) were used

to generate standard curves commencing at 1:33.3 dilution (14.85mg/mL) in 1% casein buffer.

Seroconversion between D0 and D21 was considered as a 2-fold rise in antibody titre, or 4-

fold rise in antibody titre if raw optical density measurements were <0.25 at baseline, as per

previously published definitions [15]

In order to measure antibody titres to the additional vaccine antigens Group A carbohydrate

(GAC) and Streptolysin O (SLO), an optimized 4-plex (GAC, SLO, SpyCEP, SpyAD) serology

assay using the Luminex platform was performed on all available sera using protocol described

[16]. All antigens were supplied by GSK Vaccine Institute for Global Health (GVGH). All sera

with ELISA data were tested, except two samples from non-colonized participants, where there

was no remaining volume. Samples were tested in duplicate at a dilution of 1:8100 alongside

standard curves derived from pooled intravenous immunoglobulin (Privigen, CSL Behring).

Mean florescence intensity was measured for each antigen with a Luminex 200 instrument

(Invitrogen).

Statistical analysis: All statistical analysis was performed in R (version 4.0.1). Comparison of

S. pyogenes colonization status and incident acquisition between children who received LAIV

and those who did not was performed using chi-squared test. In addition, logistic and

generalized mixed effects logistic regression models, accounting for multiple timepoint

sampling from individuals, were used to explore the change in colonization status over time

within the vaccinated and unvaccinated groups, as previously described [10]. Co-variates

included were age in months, sex, the presence of asymptomatic respiratory viruses at baseline,

timepoint (D0 vs D7, D0 vs D21) and receipt of LAIV [10, 11].

Samples where optical density measured by ELISA fell below the detection limit of the

standard curve, were allocated a random value between zero and the limit of detection.

Antibody titres in Luminex data were interpolated using xPonent 4.2 software (Luminex

Corporation) using 5-parameter logistic regression. For the 4-plex Luminex assay, where both

limit of accurate quantification and detection were characterized, results falling below

respective limits were randomly assigned a value between zero and the lowest value of each

limit [16]. Antibody data (IVIG–adjusted anti-protein activity in mg/mL for ELISA and

Relative Luminex Units (RLU/mL) for Luminex assay) were Log transformed and assessed for

normality using QQplot and the shapiro-wilk test. Log transformed antibody quantities

between groups were compared using Student's t-test. Paired Student's t-test was performed to

compare antibody levels before and after *S. pyogenes* colonization from individual participants.

A *p* value of <0.05 was considered statistically significant.

Results

<u>*S. pyogenes* colonization prevalence and incidence</u>: A total of 320 participants were included

in this study, of which 212 received LAIV (Figure 1). Overall, 71/320 (22%) children were

colonized with *S. pyogenes* on at least one time point within the 21-day study period. At D0

26/320 (8%) participants were colonized, 13 in the LAIV (6%) and 13 in control (12%) groups

(p=0.068, Table S1). In the acquisition study group, 45 (15%) had acquired colonization by

D7 or D21 (Table 1), 35/199 (18%) in LAIV group and 10/95 (11%) in control group (Table

1, p=0.12). A logistic regression model was used to explore the odds of new *S. pyogenes*

colonization at either D7 or D21 in the acquisition study group (n=294), accounting for age,

sex, LAIV receipt and the presence of other respiratory viruses at D0 (Table S2), showing no

significant association between LAIV and *S. pyogenes* acquisition (OR 1.92, 0.93-4.31,

p=0.09).

Figure 1. Study profile. *320 participants randomized 2:1 to the LAIV (day 0 vaccine) or control (day 21 vaccine) group. All participants (colonization study group) had S. pyogenes colonization status determined by real-time PCR at day 0, 7 and 21. 294 participants (the acquisition study group) were negative at baseline. Only participants receiving LAIV at day 0 had serum taken at days 0 and 21 (n=212). Serum from day 21 was available from 40/48 participants from LAIV group who were colonized at any time point and from 61/164 randomly selected non-colonized participants. Paired serum (pre/post colonization) was available from 18/35 participants who acquired colonization during the study period. LAIV = Live attenuated Influenza Vaccine.*

Table 1. Streptococcus pyogenes acquisition during the 21-day study period. *Included below are n=294 in the acquisition study group.*

Time point	N	Overall, N = 294[1]	Control, N = 95[1]	LAIV, N = 199[1]	p-value[2]
Day 7	294	18 (6%)	3 (3%)	15 (8%)	0.14
Day 21	294	35 (12%)	8 (8%)	27 (14%)	0.2
Any time	294	45 (15%)	10 (11%)	35 (18%)	0.12

[1]n(%)

[2]Pearson's Chi-squared test

In order to explore changes in colonization status within an individual over time in all children (n=320), a generalized logistic mixed effects regression model was used to explore the odds of *S. pyogenes* colonization over time, accounting for age, sex, LAIV receipt and the presence of other respiratory viruses at D0 (Table S3). As an interaction was observed between LAIV receipt and the D21 timepoint terms in this model, we constructed separate models for the LAIV and control groups. The odds ratio (OR) of *S. pyogenes* colonization was higher at D21 compared to day D0 in the LAIV group (OR 3.18, 95% CI 1.49-6.81, p=0.003, Table 2) but not day 7 (OR 1.30, 95% CI 0.57-2.97, p=0.54). The OR of *S. pyogenes* colonization in the control group was not higher at either D7 (OR 0.34, 95% CI 0.09-1.27, p=0.11) or D21 (OR 0.86, 95% CI 0.3-2.51, p=0.79) when compared to D0 (Table S4).

Only 17 of 71 (23.9%) participants with *S. pyogenes* detected during the study were colonized at two timepoints, with only 2 (2.8%) colonized at all three study time points (Figure S1). No difference in qPCR quantified *S. pyogenes* density was observed between LAIV and control participants at any timepoint nor over time (Table S5).

Table 2. Factors associated with S. pyogenes colonization in the live attenuated influenza vaccine (LAIV) group.

	OR	95% CI	p-value
Day 7 (vs day 0)	1.30	0.57-2.97	0.540
Day 21 (vs day 0)	3.18	1.49-6.81	**0.003**
Positive respiratory virus at day 0	1.54	0.72-3.29	0.266
Age in months	0.97	0.93-1.01	0.162
Sex Male (vs female)	0.97	0.47-2.04	0.945

p-values for factors associated with Streptococcus pyogenes colonization are derived from a generalized logistic mixed effects model, taking into account changes within individuals over time. OR = odds ratio, CI = confidence interval.

We compared symptom data during the study period for all 294 children in the acquisition study group. Ten children had infected skin sores during the 21-day follow up, 9 in the LAIV group and 1 in the control group (5% vs 1%, p=0.2, Table S6). Only three episodes of sore throat were reported, all in the LAIV group (Table S6). Skin sores were more common in those who became colonized (9% vs 2% p=0.05) (Table S6). No statistically significant difference in fever, cough, rhinorrhoea, or sore throat was seen in children who acquired *S. pyogenes* compared to those who did not (Table S6). In the total study group only 6/71 (9%) colonized participants had either a sore throat or an infected skin sore.

<u>Serological responses to *S. pyogenes* antigens</u>: ELISA-quantified serum antibody titres at D21

in 40 colonized participants were compared with those in 61 randomly selected non-colonized

participants (all from the LAIV group due to sera availability). The age was not significantly

different between participants included in serological study who were colonized compared to

non-colonized controls (median age in months 36 vs 32, p=0.3, Table S6). Sera from colonized

participants demonstrated significantly higher IVIG-adjusted IgG levels to M1, SpyCEP,

SpyAD and Mac, but not Cpa, compared to non-colonized participants (Figure 2A). Paired

serum was available for 18/35 newly-colonized participants. Mean M1- and SpyCEP-specific

IgG titres were significantly increased at D21 compared to D0, but not IgG titers to SpyAD,

Mac or Cpa (Figure 2B). The proportion of newly-colonized participants who seroconverted

pre/post colonization was greatest for M1 and SpyCEP (Figure 2C). To explore serological

responses further, a recently described 4-plex assay was used to quantify antibodies to

additional *S. pyogenes* vaccine antigens GAC and SLO, along with SpyCEP and SpyAD. This

assay was tested on 99/101 samples with ELISA-quantified anti-*S. pyogenes* titres [16]. Sera

from colonized children demonstrated significantly higher titres to GAC, SLO and SpyCEP

but not to SpyAD (Figure 3A). In the subset of participants with *S. pyogenes* acquisition during

the 21-day study period (n=18), differences in IgG titers at D0 and D21 were not statistically

significant (Figure 3B). Antibody titres to SpyCEP and SpyAD that were measured by both

techniques were well correlated (Figure S2). Removing the participants with sore throat or

infected skin sores and colonization during the study had no significant impact on the

serological results, nor did excluding participants colonized on D21 only, nor applying a more

conservative definition of seroconversion (4-fold increase in IgG titre regardless of baseline

optical density) (Figures S3, S4, S5).

*Figure 2. Serological responses to S. pyogenes colonization measured by ELISA. **A.***
Comparison of anti-protein IgG activity to Cpa, M1, Mac, SpyCEP, and SpyAD in participants
*(n=101) according to anytime S. pyogenes colonization status. **B**. Paired comparison of anti-*
protein IgG activity to Cpa, M1, Mac, SpyCEP, and SpyAD between day 0 and day 21 in newly
colonized participants (n=18). Log$_{10}$ transformed IVIG-adjusted anti-protein activity was
compared with t-tests (unpaired and paired respectively), horizontal line depicts the median
*value. **C**. Percentage of study participants (n=18) acquiring S. pyogenes during the study who*
seroconverted between day 0 and day 21.

Figure 3. Serological responses to S. pyogenes colonization measured by Luminex 4-plex.

A. *Comparison of IgG activity to GAC, SLO, SpyCEP, and SpyAD in participants (n=99)*

according to anytime S. pyogenes colonization status. ***B***. *Paired comparison of IgG activity to*

GAC, SLO, SpyCEP, and SpyAD between D0 and D21 in newly-colonized participants (n=18).

Log$_{10}$ transformed IVIG-adjusted anti-antigen activity was compared with t-tests (unpaired and

paired respectively). Horizontal bar depicts the median value.

Discussion

In this post-hoc study of a randomized controlled trial set in The Gambia, we report to our

knowledge the first analysis examining the impact of LAIV on *S. pyogenes* nasopharyngeal

colonization in children. Using PCR to define colonization events, we observed a prevalence

of 8% at the start of the study in children aged 24-59 months. Our data demonstrate only a

modest impact of LAIV on *S. pyogenes* colonization rates. We observed non-significantly

increased rates and odds of new colonization in the LAIV group and increased odds of

colonization at D21 compared to baseline in the LAIV group only. During the short 21-day study duration, 22% of children were colonized at one or more timepoints, with most children (73%) only colonized at one timepoint. The dynamic picture of colonization we observed may be partially influenced by LAIV administration. It may also reflect how commonly children are exposed to *S. pyogenes* in areas with a high burden of *S. pyogenes* disease and our findings are broadly in keeping with published estimates from LMICs [4, 17].

S. pyogenes was demonstrated to be responsible for substantial mortality in influenza pandemics of 1918 and 2009 [8, 9]. While both epidemiological and mechanistic observations demonstrate that respiratory viruses, including influenza, are associated with severe *S. pyogenes* disease, their role in modulating the host-pathogen interaction is complex and poorly understood, particularly in relation to colonization of the pharynx [8, 9, 18-21]. As respiratory viruses frequently infect the colonizing sites of bacteria, it is important to understand their impact on potentially pathogenic bacteria such as *S. pyogenes*. While mice administered a non-lethal challenge with *S. pyogenes* following an influenza challenge frequently had a severe and fatal disease course [21], mice vaccinated with LAIV were protected from *S. pyogenes* superinfection [20], but few models have specifically investigated the impact of respiratory viruses on pharyngeal colonization [22]. With the recent establishment of a *S. pyogenes* human challenge model, co-challenge studies with LAIV and *S. pyogenes* could reveal mechanistic insights into the interaction between influenza virus, *S. pyogenes*, and host immune responses [23]. A co-challenge study with *S. pneumoniae* and LAIV has shown how virus-induced inflammatory responses and impaired innate immune responses promote bacterial colonization [24]. The data provide further evidence that the impact of LAIV on colonization with potentially pathogenic bacteria is only modest and supports the wider rollout of LAIV to reduce influenza disease and its complications in LMICs.

We also demonstrate that asymptomatic *S. pyogenes* colonization leads to seroconversion to

several antigens representative of different stages in *S. pyogenes* infection, with differences in

antibody magnitude across the different targets measured[14]. Higher serological responses to

S. pyogenes antigens were observed in children colonized at any timepoint in our study

compared to non-colonized controls. Given that prior exposure to *S. pyogenes* in all children

in this cohort may be similar, these differences likely reflect recent exposure. The most notable

responses were seen to full length streptococcal M1 protein and to the envelope protease

SpyCEP when measured by ELISA, including a rise in titres in paired sera taken from before

and after colonization. Reactivity to full length M1 protein likely reflects activity to conserved

M protein region rather than type-specific reactivity, given that *emm*1 isolates have not been

identified in The Gambia[25, 26]. IgG antibodies to other antigens, SpyAD, Mac, GAC and

SLO, were higher in children where *S. pyogenes* colonization had been detected, but not Cpa.

Noting that the antigens tested via ELISA and Luminex were obtained from different sources,

there was broad concurrence between the two serological assays, except that IgG to SpyAD

was significantly higher in colonized compared to non-colonized participants when measured

by ELISA and not by Luminex. Nonetheless, our findings suggest that asymptomatic

pharyngeal colonization with *S. pyogenes* may indeed elicit an IgG immunological response to

multiple antigens.

Whilst "true" *S. pyogenes* colonization has been defined as colonization *without* a serological

response, the definition risks simplification of a complex and dynamic state influenced by host-

immunity, bacterial characteristics, and environmental factors. This serologically inactive

phenotype has been described with minimal serum antibody response to SLO and anti-DNAase

B (7, 32). Our data shows that serological responses are variable following asymptomatic

colonization to different proteins. Furthermore, in practice colonization is often defined as an

asymptomatic person with detectable *S. pyogenes* without serial serological testing. In detailed

longitudinal analyses, seroconversion has been documented following asymptomatic

acquisition of *S. pyogenes* in the USA and Egypt, with highest proportion of seroconversions

to type-specific M peptides and SpyAD [15, 27].   In another cohort study in the USA,

seroconversion to type-specific M protein frequently occurred following asymptomatic

acquisition and conferred protection from homologous strain reinfection [28].

Protection following asymptomatic colonization and historical *S. pyogenes* intranasal

vaccination has been observed, but the responsible mechanisms and serological corelates of

protection have not been identified [29-34]. Early prospective observation demonstrated the

emergence of acute rheumatic fever following asymptomatic *S. pyogenes* infection [35].

Furthermore, emerging data show that patients with rheumatic fever have serological activity

to significantly more *S. pyogenes* M peptides and conserved antigens compared to matched

controls, including activity following asymptomatic pharyngeal colonization [36, 37]. It is

therefore possible that asymptomatic colonization could play a role in the pathological

immunity that leads to acute rheumatic fever in endemic settings and warrants further

exploration.

Our study has several key limitations. Firstly, it was a post-hoc analysis of a study principally

powered for assessing the impact of LAIV on *S. pneumoniae* colonization density, and

interactions between the host microbiome and LAIV-specific immunity. The study was not

powered to detect any impact of LAIV on *S. pyogenes* density. LAIV is used as a proxy for

natural influenza infection and may not reflect the true dynamics of *S. pyogenes* colonization

during natural influenza infection. We defined colonization events by PCR and not

microbiological culture of *S. pyogenes*, which is considered the gold standard for defining the

presence of *S. pyogenes*. We have previously demonstrated that the point prevalence of

pyoderma in children under 5 from the same community is high at 17.4%, with *S. pyogenes*

cultured from 51% of pyoderma lesions [38]. We did not perform microbiological culture on

infected skin lesions or from sore throats in this study to be able to definitively categorize these

episodes as symptomatic S. pyogenes events. Nonetheless the exclusion of all participants with

either a sore throat or skin sore did not dramatically alter the serological findings. Due to the

availability of serum samples, we only measured *S. pyogenes*-specific antibodies in in the

LAIV group, so no comparison between vaccinated and unvaccinated groups was possible.

Finally, PCR to a single preserved and specific *S. pyogenes* target does not allow for assessment

of *emm*-type specific immunity, which is an historically important consideration for *S.*

pyogenes serological activity.

Nonetheless, our study does provide several important findings. Understanding both naturally

occurring protective immunity and pathological autoimmunity to *S. pyogenes* from settings

with the highest disease burden is of paramount importance to progress towards a safe and

effective *S. pyogenes* vaccine. Our study adds further evidence that asymptomatic colonization

may be immunologically significant, particularly in the context of influenza co-infection.

Further research combining longitudinal observation, with detailed microbiological and

immunological investigation should be prioritised from areas of high disease prevalence to gain

a deeper understanding of immunity to this major human pathogen.

Acknowledgements

The authors would like to acknowledge and thank the Strep A Study Group at Medical

Research Council (MRC) Unit The Gambia at London School of Hygiene & Tropical Medicine

(LSHTM), Sona Jabang, Annette Erhart, Saffiatou Darboe, Abdul Karim Sesay, Peggy-Estelle

Tiencheu, Saikou Y. Bah, Lamin Jaiteh, Karen Forrest, Anna Roca, Fatoumata Camara; Peggy-

Estelle Tiencheu , Aru-Kumba Baldeh, Grant Mackenzie, Martin Antonio; GSK Vaccine

Institute of Global Health, particularly Danilo Moriel and Luisa Masai for the technical support

and provision of SpyCEP, Slo, GAC and SpyAD antigens for measuring IgG in Luminex 4-

plex assay; the dedicated team of field and nursing staff, especially Sulayman Bah and Janko

Camara, who delivered the study at MRC Unit The Gambia at LSHTM; Isatou Ndow for

clinical trial organization; the research support and clinical trials support offices at the Unit the

Serum Institute of India for donating the vaccines for the study. Most importantly we thank the

study participants and their parents who took part in the study.

References:

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A

streptococcal diseases. Lancet Infect Dis **2005**; 5:685-94.

2. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of

Rheumatic Heart Disease, 1990-2015. N Engl J Med **2017**; 377:713-22.

3. World Health O. WHO preferred product characteristics for group A streptococcus

vaccines. Geneva: World Health Organization, **2018**.

4. Oliver J, Malliya Wadu E, Pierse N, Moreland NJ, Williamson DA, Baker MG. Group A

Streptococcus pharyngitis and pharyngeal carriage: A meta-analysis. PLoS Negl Trop Dis

2018; 12:e0006335.

5. Vekemans J, Gouvea-Reis F, Kim JH, et al. The Path to Group A Streptococcus Vaccines:

World Health Organization Research and Development Technology Roadmap and Preferred

Product Characteristics. Clinical Infectious Diseases **2019**; 69:877-83.

6. Martin J. The Streptococcus pyogenes Carrier State. In: Ferretti JJ, Stevens DL, Fischetti

VA, eds. Streptococcus pyogenes : Basic Biology to Clinical Manifestations. Oklahoma City

(OK), **2016**.

7. Kaplan EL. The group A streptococcal upper respiratory tract carrier state: an enigma. J

Pediatr **1980**; 97:337-45.

8. Louie J, Jean C, Chen TH, et al. Bacterial Coinfections in Lung Tissue Specimens from Fatal

Cases of 2009 Pandemic Influenza A (H1N1) - United States, May-August 2009. Atlanta,

United States: U.S. Center for Disease Control, **2009**:1071-4.

9. Morens DM, Fauci AS. The 1918 Influenza Pandemic: Insights for the 21st Century. The

Journal of Infectious Diseases **2007**; 195:1018-28.

10. Peno C, Armitage EP, Clerc M, et al. The effect of live attenuated influenza vaccine on

pneumococcal colonisation densities among children aged 24-59 months in The Gambia: a

phase 4, open label, randomised, controlled trial. Lancet Microbe **2021**; 2:e656-e65.

11. Lindsey BB, Jagne YJ, Armitage EP, et al. Effect of a Russian-backbone live-attenuated

influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity

among children in The Gambia: an open-label, observational, phase 4 study. The Lancet

Respiratory medicine **2019**; 7:665-76.

12. Biesbroek G, Sanders EAM, Roeselers G, et al. Deep Sequencing Analyses of Low Density

Microbial Communities: Working at the Boundary of Accurate Microbiota Detection. PLOS

ONE **2012**; 7:e32942.

13. Dunne EM, Marshall JL, Baker CA, et al. Detection of group a streptococcal pharyngitis by

quantitative PCR. BMC Infectious Diseases **2013**; 13:312.

14. Shaw HA, Ozanne J, Burns K, Mawas F. Multicomponent Vaccines against Group A

Streptococcus Can Effectively Target Broad Disease Presentations. Vaccines. Vol. 9, **2021**.

15. Hysmith ND, Kaplan EL, Cleary PP, Johnson DR, Penfound TA, Dale JB. Prospective

Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal

Acquisition of Group A Streptococci. Journal of the Pediatric Infectious Diseases Society

2017; 6:187-96.

16. Keeley AJ, Carducci M, Massai L, et al. Development and Characterisation of a Four-Plex

Assay to Measure Streptococcus pyogenes Antigen-Specific IgG in Human Sera. Methods

Protoc **2022**; 5.

17. DeWyer A, Scheel A, Webel AR, et al. Prevalence of group A β-hemolytic streptococcal

throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan

school children. Int J Infect Dis **2020**; 93:245-51.

18. de Gier B, Vlaminckx BJM, Woudt SHS, van Sorge NM, van Asten L. Associations between

common respiratory viruses and invasive group A streptococcal infection: A time-series

analysis. Influenza and Other Respiratory Viruses **2019**; 13:453-8.

19. Okahashi N, Sumitomo T, Nakata M, Kawabata S. Secondary streptococcal infection

following influenza. Microbiology and Immunology **2022**; 66:253-63.

20. Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with

formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus

pyogenes superinfection. Vaccine **2004**; 22:2887-93.

21. Okamoto S, Kawabata S, Nakagawa I, et al. Influenza A virus-infected hosts boost an

invasive type of Streptococcus pyogenes infection in mice. J Virol **2003**; 77:4104-12.

22. Bai X, Yang W, Luan X, et al. Induction of cyclophilin A by influenza A virus infection

facilitates group A Streptococcus coinfection. Cell Reports **2021**; 35:109159.

23. Osowicki J, Azzopardi KI, Fabri L, et al. A controlled human infection model of

Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study.

The Lancet Microbe **2021**; 2:e291-e9.

24. Jochems SP, Marcon F, Carniel BF, et al. Inflammation induced by influenza virus impairs

human innate immune control of pneumococcus. Nature Immunology **2018**; 19:1299-308.

25. Bah SY, Keeley AJ, Armitage EP, et al. Comparative genomic analysis of skin and soft

tissue Streptococcus pyogenes isolates from low- and high-income

settings. bioRxiv **2021**:2021.09.10.459590.

26. Jabang S, Erhart A, Darboe S, et al. Molecular Epidemiology of Group A Streptococcus

Infections in The Gambia. Vaccines **2021**; 9.

27. el-Kholy A, Sorour AH, Houser HB, et al. A three-year prospective study of streptococcal

infections in a population of rural Egyptian school children. J Med Microbiol **1973**; 6:101-10.

28. Dunlap MB, Harvey HS. The Carrier State and Type-Specific Immunity in Streptococcal

Disease. American Journal of Diseases of Children **1967**; 114:229-43.

29. Bloomfield AL, Felty AR. Prophylactic vaccination against acute tonsillitis. Bull Johns

Hopkins Hosp **1923**; 34:251-3.

30. Lewnard JA, Whittles LK, Rick AM, Martin JM. Naturally Acquired Protection Against

Upper Respiratory Symptoms Involving Group A Streptococcus in a Longitudinal Cohort

Study. Clin Infect Dis **2020**; 71:e244-e54.

31. D'Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal

M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization

with Type 3 or Type 12 group A Streptococcus. J Infect Dis **1978**; 138:712-8.

32. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A. Protective studies with a group

A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the

upper respiratory tract. J Infect Dis **1975**; 131:217-24.

33. Tsoi SK, Smeesters PR, Frost HRC, Licciardi P, Steer AC. Correlates of Protection for M

Protein-Based Vaccines against Group A Streptococcus. Journal of immunology research

2015; 2015:167089-.

34. Cope JB, Redys JJ, Randolph MF. A Comparison of Two Streptococcal Antibody Levels in

Posttreatment Carriers of Group A Streptococci: The Relationship between Elevated Titers

and Clinical Relapse as Determined by a New Serologic Procedure. Clinical Pediatrics **1976**;

15:1120-2.

35. Gordis L, Lilienfeld A, Romeo R. An Evaluation of the Maryland Rheumatic Fever Registry.

Public Health Reports (1896-1970) **1969**; 84:333-9.

36. Lorenz N, Ho TK, McGregor R, et al. Serological profiling of group A Streptococcus

infections in acute rheumatic fever. Clinical Infectious Diseases **2021**; 73:2322-5.

37. Whitcombe AL, McGregor R, Bennett J, et al. Increased breadth of Group A

Streptococcus antibody responses in children with Acute Rheumatic Fever compared to

precursor pharyngitis and skin infections. The Journal of Infectious Diseases **2022**:jiac043.

38. Armitage EP, Senghore E, Darboe S, et al. High burden and seasonal variation of

paediatric scabies and pyoderma prevalence in The Gambia: A cross-sectional study. PLoS

neglected tropical diseases **2019**; 13:e0007801.

Footnote Page

Funding:

This research was funded by Wellcome Trust in part by an Intermediate Clinical Fellowship

award to TIdS [Grant no: 110058/Z/15/Z] and in part by a Clinical PhD fellowship in Global

Health award to AJK [Grant no: 225467/Z/22/Z]. For the purpose of open access, the author

has applied a CC BY public copyright licence to any Author Accepted Manuscript version

arising from this submission.

Conflicts of interest.

O.R. and M.C are employees of the GSK group of companies. GSK Vaccines Institute for

Global Health Srl is an affiliate of GlaxoSmithKline Biologicals SA. OR reports ownership

of GSK share options. We declare there are no conflicts of interest among other authors

Corresponding Author:

Alexander Keeley, Vaccines and Immunity Theme, MRC Unit The Gambia at LSHTM, PO

Box 273, Banjul, The Gambia, alexander.keeley@lshtm.ac.uk

Previous presentation:

The preliminary data from this study were presented at Lancefield Symposium for

Streptococcal and Streptococcal Diseases, Stockholm 2022, and at European Congress of

Clinical Microbiology and Infectious Diseases 2021, Online.